Medical/Pharmaceuticals

Clarivate Introduces New OFF-X ™ Platform for Preclinical and Clinical Safety Intelligence

Empowering biopharma with enhanced safety insights to anticipate risks and unlock new competitive advantages LONDON, July 30, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the launch of the newOFF-X™ platform. The enhance...

2024-07-30 15:00 1565

Synthetica Pioneering Closes a Series A Funding Round to Support Development of Oncolytic Bacterial Therapy for Solid Tumors

SHENZHEN, China, July 30, 2024 /PRNewswire/ -- Shenzhen Synthetica Pioneering Co., Ltd. (Synthetica), a biotech startup specializing in synthetic biology for engineering novel living bacterial therapeutics, has recently closed a Series A funding round, led by Boehringer Ingelheim Venture Fund and...

2024-07-30 14:00 1603

Baxter's Helion System Launches in Thailand, Bringing Comprehensive Simplicity to ORs

BANGKOK, July 30, 2024 /PRNewswire/ -- Baxter International Inc . (NYSE: BAX), a global MedTech leader, announced the launch of theHelion Integrated Surgical System in Thailand. Leveraging operating room integration (ORI) and cutting-edge technology, Helion simplifies op...

2024-07-30 10:23 2605

NCCN and Medlive Renew Collaboration to Enhance Cancer Care in China

United States-based National Comprehensive Cancer Network strengthens relationship with Chinese medical platform Medlive to broaden access to eminent oncology guidelines inChina PLYMOUTH MEETING, Pa., July 30, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®), an alliance o...

2024-07-30 09:02 1730

NEURIM PHARMACEUTICALS RECEIVES POSITIVE CHMP OPINION ON SLENYTO® (PEDIATRIC PROLONGED-RELEASE MELATONIN) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH NEUROGENETIC DISORDERS (NGDs)

TEL-AVIV, Israel, July 30, 2024 /PRNewswire/ -- Neurim Pharmaceuticals ("Neurim") announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending an extension to the existing ind...

2024-07-30 09:00 3332

Bridge Biotherapeutics Announces Completion of Enrollment in the Phase 2a Clinical Study of BBT-877 for the Treatment of Idiopathic Pulmonary Fibrosis

SEONGNAM, South Korea, July 29, 2024 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based inSouth Korea developing novel drugs for fibrosis and cancer, today announced that patient participant enrollment has been completed in the Phase 2 clinical study of BBT-...

2024-07-30 06:00 1532

CSafe launches reusable Silverpod pallet shipper to help pharma companies save on disposal costs and hit sustainability targets

New pallet improves cost and operational efficiency while reducing environmental impact; includes real-time visibility with cloud connectivity Key features include: * Made of fully reusable components and recyclable PCM (phase change material) refrigerants * New integrated real-time tracking...

2024-07-30 02:00 1873

Menarini Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Efficacy, Safety and Tolerability of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia

-- Achieved primary endpoint of LS mean reduction in LDL-C on top of maximally tolerated lipid modifying therapies at week 12 with statistically significant reduction (p<0.0001), which was sustained at week 52 (p<0.0001) -- -- Obicetrapib lowered LDL-C by 36.3% at week 12 and by 41.5% at week 52,...

2024-07-29 23:18 2285

SOPHiA GENETICS Announces L'hôpital Universitaire Avicenne is Live on SOPHiA DDM™

The hospital will use the SOPHiA DDM™ Platform to enhance its testing and research of blood cancers BOSTON and ROLLE, Switzerland, July 29, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, today announced that...

2024-07-29 22:30 1673

Daewoong Pharmaceutical Receives Positive Recommendation from IDMC to Continue Developing its First-in-Class PRS Inhibitor, Bersiporocin

SEOUL, South Korea, July 29, 2024 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOsChang-Jae Lee and Seongsoo Park) announced a significant milestone in the development of 'Bersiporocin (DWN12088)', a first-in-class PRS inhibitor for idiopathic pulmonary fibrosis (IPF), has taken a significant ste...

2024-07-29 20:00 1796

Despite External Challenges, WuXi AppTec Maintained Stable Operations in First Half of 2024; Revenue and Profit of the Second Quarter Both Steadily Improved QoQ as Expected, with Revenue Up 16.0% QoQ and Adjusted Non-IFRS Net Profit Up 28.5% QoQ

* Revenue Reached RMB9,259 Million in the Second Quarter, Excluding COVID-19 Commercial Projects, Up 0.3% Year-over-Year * Revenue Reached RMB17,241 Million for the First Half, Excluding COVID-19 Commercial Projects, Down 0.7% Year-over-Year * Net Profit Attributable to the Owners of the Com...

2024-07-29 19:05 4312

EXPOSURE TO WILDFIRE SMOKE GREATLY RAISES RISK OF DEMENTIA DIAGNOSIS

Key Takeaways * Wildfire smoke may be particularly hazardous to brain health, according to a 10-year study of more than 1.2 million southern Californians.  * Exposure to wildfire smoke increases the risk of being diagnosed with dementia more than other forms of air pollution.   * The risk o...

2024-07-29 19:00 1711

Akeso's sBLA for Ivonescimab in 1L Treatment of PD-L1 Positive NSCLC Accepted by NMPA

HONG KONG, July 29, 2024 /PRNewswire/ -- Akeso (9926.HK) is delighted to announce that the supplemental biologics license application (sBLA) for its independently developed, world's first-in-class PD-1/VEGF bispecific antibody drug, 依达方® (generic name: ivonescimab Injection), as a monotherapy for...

2024-07-29 17:26 1744

Global Icon Malala Yousafzai to Headline APACMed's MedTech Forum in Singapore

SINGAPORE, July 29, 2024 /PRNewswire/ -- APACMed is thrilled to announce that Nobel Laureate and global iconMalala Yousafzai will take centre stage at this year's MedTech Forum, taking place onSeptember 5th and 6th at the Suntec Convention Centre. This highly anticipated event focuses squarely on...

2024-07-29 13:44 9981

111 to Announce Second Quarter 2024 Unaudited Financial Results on August 29, 2024 - Conference Call to Follow

SHANGHAI, July 29, 2024 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, today announced that it will repor...

2024-07-29 13:00 1628

A.MENARINI, CARiNG PHARMACY AND ACT4HEALTH JOIN FORCES TO DRIVE MILD COGNITIVE IMPAIRMENT EARLY DETECTION WITH A FREE VISUAL COGNITIVE ASSESSMENT TEST

-  Awareness and early-stage detection of Mild Cognitive Impairment (MCI) for prevention. -  Free Visual Cognitive Assessment Test (VCAT) screening at selected CARiNG Pharmacy Malaysia outlets. KUALA LUMPUR, Malaysia, July 29, 2024 /PRNewswire/ -- A. Menarini, a wholly owned subsidiary of the M...

2024-07-29 11:20 2193

ALZHEIMER'S DISEASE BLOOD TESTS COULD IMPROVE DIAGNOSIS IN PRIMARY CARE, SPEED RECRUITING FOR RESEARCH & REDUCE WAIT TIMES

Key Takeaways * Blood tests that accurately and reliably detect Alzheimer's hallmark brain changes signal a shift to simpler, more accurate and earlier detection and diagnosis, potentially superseding current methods that are expensive, invasive and not always accessible. * A blood test was ...

2024-07-29 08:50 1875

Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for Treating Schizophrenia and Schizoaffective Disorder

PRINCETON, N.J., July 28, 2024 /PRNewswire/ -- Luye Pharma Group (Luye Pharma), an international pharmaceutical company dedicated to the R&D, manufacturing and sales of innovative medications, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's ERZOFRI® (pa...

2024-07-28 21:48 3008

Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation

* The positive CHMP opinion is based on results from the Phase II PHAROS trial,[1] which demonstrated an objective response rate (ORR) of 75% in treatment-naïve patients and 46% in previously treated patients. The safety profile is consistent with that observed in the approved metastatic melano...

2024-07-26 23:21 5701

MHX Jakarta 18-21 July 2024 Wrapped Up with Record Turnout, High Leads Generation and Strategic Partnerships

JAKARTA, Indonesia, July 26, 2024 /PRNewswire/ -- Malaysia Healthcare Travel Council (MHTC) achieved impressive results in numerous fronts inJakarta! MHTC is the pioneer in organising healthcare expo inIndonesia and the inaugural event was in Semarang in 2012. MHTC has successfully organised two ...

2024-07-26 21:02 5856
1 ... 40414243444546 ... 610

Week's Top Stories